---
title: "What Is Retatrutide? The Triple Agonist, Explained"
canonical_url: https://peptidelibrary.app/blog/what-is-retatrutide
description: "Retatrutide is the first triple agonist to reach late-stage obesity trials. Understanding it means understanding what a third receptor adds to an already effective pair."
updated: 2026-09-10
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# What Is Retatrutide? The Triple Agonist, Explained

Retatrutide is the first triple agonist to reach late-stage obesity trials. Understanding it means understanding what a third receptor adds to an already effective pair.

**Retatrutide is an investigational peptide that activates three receptors at once: GIP, GLP-1, and glucagon.** Semaglutide activates one. Tirzepatide activates two. Retatrutide adds the third.

That progression is the simplest way to understand where it sits, and why its phase 2 results attracted the attention they did.

> **Investigational, not approved. **Retatrutide has no approved indication anywhere and no established dose. Everything here is published trial data reported for reference, not dosing guidance.

## The three receptors

| **Receptor** | **What activating it does** |
| --- | --- |
| GLP-1 | Slows gastric emptying, reduces appetite, glucose-dependent insulin release |
| GIP | Improves insulin sensitivity; may soften the nausea that limits GLP-1 activity |
| Glucagon | Increases energy expenditure and acts on the liver |

The first two act largely on how much you take in. The third acts on how much you burn. Combining both sides of the equation in one molecule is the design idea.

## What the phase 2 trial found

The NEJM phase 2 trial randomised 338 adults across placebo and four retatrutide arms, escalating gradually over 48 weeks.

| **Arm** | **Mean weight change at 48 weeks** |
| --- | --- |
| Placebo | −2.1% |

The [dosage guide](https://peptidelibrary.app/blog/retatrutide-dosage-chart) covers the escalation schedule those figures depend on.

> The endpoint figure describes the top of a slow, monitored ramp — which is also why the tolerability data belong alongside it. See [retatrutide side effects](https://peptidelibrary.app/blog/retatrutide-side-effects).

## How it compares

The obvious comparison is with tirzepatide, and it cannot be made properly: no head-to-head trial exists, and the two figures people place side by side come from different trials, durations, populations and phases. See [retatrutide vs tirzepatide](https://peptidelibrary.app/blog/retatrutide-vs-tirzepatide) for why that comparison does not hold.

[Survodutide](https://peptidelibrary.app/blog/survodutide) takes a different route to a similar idea — GLP-1 plus glucagon, without GIP — which makes the three of them a natural set to read together.

## Where it stands

Phase 3 programmes are ongoing. That stage is where efficacy is confirmed at scale and where less common adverse effects surface — and it is where a meaningful share of candidate drugs fail or acquire restrictions.

Until it reports, anything sold as retatrutide is research material outside any regulated supply chain, with no assurance of identity, purity or content. The [COA guide](https://peptidelibrary.app/blog/how-to-read-a-peptide-coa) covers what can be verified about such material.

## Frequently asked questions

### Is retatrutide approved?

No. It is in phase 3 trials with no approval in any major jurisdiction.

### What makes it different from tirzepatide?

The glucagon receptor. Tirzepatide targets GIP and GLP-1; retatrutide adds glucagon, which acts on energy expenditure and the liver.

### Is there an established dose?

No. The trial arms are the only published figures, and they came with gradual escalation under clinical monitoring.

> **Research and educational use only. **Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

## Sources

- [Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972)

Note: Dose figures are left out of this Markdown version. See the cited sources.